Dermatology Continuing Medical Education

1-16 of 23

Push Past in AD: Treatment Escalation in Moderate to Severe Atopic Dermatitis—A Regional Workshop Series for Advanced Practice Providers
Push Past in AD: Treatment Escalation in Moderate to Severe Atopic Dermatitis—A Regional Workshop Series for Advanced Practice Providers
CME/CE In-Person Event
Push Past in AD: Treatment Escalation in Moderate to Severe Atopic Dermatitis—A Regional Workshop Series for Advanced Practice Providers
November 03, 2026
New York, New York
Kristine Kucera, PA-C, MPAS, DHSc; Foday Koroma, FNP-BC, MSN
1.50 credits
The Treatment Planning Process for Atopic Dermatitis
The Treatment Planning Process for Atopic Dermatitis
Dermatology Hub: Neuroimmune Network
The Treatment Planning Process for Atopic Dermatitis
Brad Glick, DO, MPH
Brad Glick, DO, MPH
A Multidisciplinary Approach to Treating Itch
A Multidisciplinary Approach to Treating Itch
Dermatology Hub: Neuroimmune Network
A Multidisciplinary Approach to Treating Itch
J. Mark Jackson, MD
J. Mark Jackson, MD
Various Benefits of Aryl Hydrocarbon Receptor Agonists
Various Benefits of Aryl Hydrocarbon Receptor Agonists
Dermatology Dialogies: Aryl Hydrocarbon Receptor Agonism
Various Benefits of Aryl Hydrocarbon Receptor Agonists
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Tapinarof’s Place in Inflammatory Disease Treatment
Tapinarof’s Place in Inflammatory Disease Treatment
Dermatology Dialogies: Aryl Hydrocarbon Receptor Agonism
Tapinarof’s Place in Inflammatory Disease Treatment
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Mechanism of Action for Aryl Hydrocarbon Receptor Agonists
Mechanism of Action for Aryl Hydrocarbon Receptor Agonists
Dermatology Dialogies: Aryl Hydrocarbon Receptor Agonism
Mechanism of Action for Aryl Hydrocarbon Receptor Agonists
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Potential Impact of Aryl Hydrocarbon Activation on Pigment
Potential Impact of Aryl Hydrocarbon Activation on Pigment
Dermatology Dialogies: Aryl Hydrocarbon Receptor Agonism
Potential Impact of Aryl Hydrocarbon Activation on Pigment
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Skin Barrier Maintenance in Atopic Dermatitis and Psoriasis
Skin Barrier Maintenance in Atopic Dermatitis and Psoriasis
Dermatology Dialogies: Aryl Hydrocarbon Receptor Agonism
Skin Barrier Maintenance in Atopic Dermatitis and Psoriasis
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Managing Patient Expectations with Topical Therapies
Managing Patient Expectations with Topical Therapies
Dermatology Dialogies: Aryl Hydrocarbon Receptor Agonism
Managing Patient Expectations with Topical Therapies
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
Neal Bhatia, MD, FAAD; Joshua Grosshandler, MD, FAAD
CME/CE Virtual Event
Push Past in AD: Treatment Escalation in Moderate to Severe Atopic Dermatitis
Multiple dates available
Kristine Kucera, PA-C, MPAS, DHSc; Chava Bayla Wald
1.00 credit
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
CME/CE
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
Anne Marie Singh, MD
1.00 credit
Anne Marie Singh, MD
1.00 credit
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
CME/CE
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
Linda Stein Gold, MD; Bruce Strober, MD, PhD
0.25 credits
Linda Stein Gold, MD; Bruce Strober, MD, PhD
0.25 credits
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD; Paolo A. Ascierto, MD
1.00 credit 10 episodes
John M. Kirkwood, MD; Paolo A. Ascierto, MD
1.00 credit 10 episodes

Prev
1
2
Next

1/2